Dr. Zambidis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1800 Orleans Street
Bloomberg 11N
Baltimore, MD 21287Phone+1 410-955-8751Fax+1 410-614-1802
Education & Training
- Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2001 - 2004
- Washington University/B-JH/SLCH ConsortiumResidency, Pediatrics, 1998 - 2001
- University of Rochester School of Medicine and DentistryClass of 1998
Certifications & Licensure
- MD State Medical License 2001 - 2025
- American Board of Pediatrics Pediatrics
Clinical Trials
- LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Start of enrollment: 2016 Nov 02
Roles: Contact
- Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis Start of enrollment: 2021 Jul 13
Roles: Contact, Principal Investigator
- Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders Start of enrollment: 2021 Apr 19
Roles: Contact
Publications & Presentations
PubMed
- 2 citationsAntiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II intervent...Michael D Keller, Patrick J Hanley, Yueh-Yun Chi, Paibel Aguayo-Hiraldo, Christopher C Dvorak
Nature Communications. 2024-04-18 - 627 citationsGeneration of three-dimensional retinal tissue with functional photoreceptors from human iPSCsXiufeng Zhong, Christian Gutierrez, Tian Xue, Christopher Hampton, M. Natalia Vergara
Nature Communications. 2014-06-10 - 311 citationsA universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability.Paul W. Burridge, Susan A. Thompson, Michal A. Millrod, Seth H. Weinberg, Xuan Yuan
Plos One. 2011-04-08
Press Mentions
- Use of a Response-Adapted Ruxolitinib-Containing Regimen for the Treatment of Hemophagocytic LymphohistiocytosisSeptember 16th, 2020
- Use of a Response-Adapted Ruxolitinib-Containing Regimen for the Treatment of Hemophagocytic LymphohistiocytosisJuly 27th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: